schliessen

Filtern

 

Bibliotheken

Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.(Research article)(Report)

Background The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune respon... Full description

Journal Title: BMC Microbiology June 24, 2010, Vol.10, p.181
Main Author: Ravindran, Rajesh
Other Authors: Bhowmick, Sudipta , Das, Amrita , Ali, Nahid
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Cengage Learning, Inc.
ID: ISSN: 1471-2180
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_hrca231548016
title: Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.(Research article)(Report)
format: Article
creator:
  • Ravindran, Rajesh
  • Bhowmick, Sudipta
  • Das, Amrita
  • Ali, Nahid
subjects:
  • Visceral Leishmaniasis -- Care And Treatment
  • Visceral Leishmaniasis -- Research
  • Liposomes -- Research
  • Bcg -- Dosage And Administration
  • Bcg -- Research
  • Phospholipids -- Physiological Aspects
  • Phospholipids -- Research
  • Trehalose -- Research
  • Adjuvant Drugs -- Research
  • Drug Delivery Systems -- Research
ispartof: BMC Microbiology, June 24, 2010, Vol.10, p.181
description: Background The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination with LAg, to confer protection against murine VL. Results All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses were measured and significant response was observed in mice vaccinated with all the three different formulations. However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-[gamma] and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-[gamma] but lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-[gamma] and IL-4 response. Elicitation of moderate levels of prechallenge IFN-[gamma] along with optimum IL-4 corresponds with successful vaccination with liposomal LAg. Conclusion This comparative study reveals greater effectiveness of the liposomal vaccine for protection against progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.
language: English
source: Cengage Learning, Inc.
identifier: ISSN: 1471-2180
fulltext: fulltext
issn:
  • 1471-2180
  • 14712180
url: Link


@attributes
ID407895665
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid231548016
sourceidgale_hrca
recordidTN_gale_hrca231548016
sourceformatXML
sourcesystemPC
galeid231548016
display
typearticle
titleComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.(Research article)(Report)
creatorRavindran, Rajesh ; Bhowmick, Sudipta ; Das, Amrita ; Ali, Nahid
ispartofBMC Microbiology, June 24, 2010, Vol.10, p.181
identifierISSN: 1471-2180
subjectVisceral Leishmaniasis -- Care And Treatment ; Visceral Leishmaniasis -- Research ; Liposomes -- Research ; Bcg -- Dosage And Administration ; Bcg -- Research ; Phospholipids -- Physiological Aspects ; Phospholipids -- Research ; Trehalose -- Research ; Adjuvant Drugs -- Research ; Drug Delivery Systems -- Research
descriptionBackground The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination with LAg, to confer protection against murine VL. Results All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses were measured and significant response was observed in mice vaccinated with all the three different formulations. However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-[gamma] and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-[gamma] but lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-[gamma] and IL-4 response. Elicitation of moderate levels of prechallenge IFN-[gamma] along with optimum IL-4 corresponds with successful vaccination with liposomal LAg. Conclusion This comparative study reveals greater effectiveness of the liposomal vaccine for protection against progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.
languageEnglish
sourceCengage Learning, Inc.
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Ravindran, Rajesh
1Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
2Bhowmick, Sudipta
3Das, Amrita
4Ali, Nahid
titleComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.(Research article)(Report)
descriptionBackground The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination with LAg, to confer protection against murine VL. Results All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses were measured and significant response was observed in mice vaccinated with all the three different formulations. However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-[gamma] and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-[gamma] but lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-[gamma] and IL-4 response. Elicitation of moderate levels of prechallenge IFN-[gamma] along with optimum IL-4 corresponds with successful vaccination with liposomal LAg. Conclusion This comparative study reveals greater effectiveness of the liposomal vaccine for protection against progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.
subject
0Visceral leishmaniasis--Care and treatment
1Visceral leishmaniasis--Research
2Liposomes--Research
3BCG--Dosage and administration
4BCG--Research
5Phospholipids--Physiological aspects
6Phospholipids--Research
7Trehalose--Research
8Adjuvant drugs--Research
9Drug delivery systems--Research
102834
11Pharmaceutical preparations
12Biological Product (except Diagnostic) Manufacturing
13Pharmaceutical Preparation Manufacturing
14325414
15325412
general
0English
1BioMed Central Ltd.
2Cengage Learning, Inc.
sourceidgale_hrca
recordidgale_hrca231548016
issn
01471-2180
114712180
rsrctypearticle
creationdate2010
recordtypearticle
addtitleBMC Microbiology
searchscopegale_hrca
scopegale_hrca
sort
titleComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.(Research article)(Report)
authorRavindran, Rajesh ; Bhowmick, Sudipta ; Das, Amrita ; Ali, Nahid
creationdate20100624
facets
frbrgroupid-1329235208
frbrtype6
languageeng
creationdate2010
topic
0Visceral Leishmaniasis–Care And Treatment
1Visceral Leishmaniasis–Research
2Liposomes–Research
3Bcg–Dosage And Administration
4Bcg–Research
5Phospholipids–Physiological Aspects
6Phospholipids–Research
7Trehalose–Research
8Adjuvant Drugs–Research
9Drug Delivery Systems–Research
collectionHealth Reference Center Academic (Gale)
prefilterarticles
rsrctypearticles
creatorcontrib
0Ravindran, Rajesh
1Bhowmick, Sudipta
2Das, Amrita
3Ali, Nahid
jtitleBMC Microbiology
toplevelpeer_reviewed
frbr
t2
k12010
k214712180
k410
k6181
k7bmc microbiology
k8comparison of bcg mpl cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis
k9comparisonofbcgmplaniasis
k12comparisonofbcgmplandcati
k15rajeshravindran
k16ravindranrajesh
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typeaggregator
addata
au
0Ravindran, Rajesh
1Bhowmick, Sudipta
2Das, Amrita
3Ali, Nahid
atitleComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
jtitleBMC Microbiology
risdate20100624
volume10
spage181
issn1471-2180
genrearticle
ristypeJOUR
abstractBackground The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination with LAg, to confer protection against murine VL. Results All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses were measured and significant response was observed in mice vaccinated with all the three different formulations. However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-[gamma] and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-[gamma] but lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-[gamma] and IL-4 response. Elicitation of moderate levels of prechallenge IFN-[gamma] along with optimum IL-4 corresponds with successful vaccination with liposomal LAg. Conclusion This comparative study reveals greater effectiveness of the liposomal vaccine for protection against progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.
pubBioMed Central Ltd.
lad01gale_hrca
date2010-06-24